Press release
Illumina Reports Financial Results for Fourth Quarter and Fiscal Year 2022
Revenue of $1.08 billion for Q4 2022, down 10% from Q4 2021, and down 7% on a constant currency basisRevenue of $4.58 billion for fiscal year 2022, up 1% from
About this update from Illumina, Inc.
[{"type":"text","content":"Revenue of $1.08 billion for Q4 2022, down 10% from Q4 2021, and down 7% on a constant currency basisRevenue of $4.58 billion for fiscal year 2022, up 1% from fiscal year 2021, and up 3% on a constant currency basisGAAP diluted loss per share of $(0.89) for Q4 2022, compared to GAAP diluted earnings per share of $0.71 for Q4 2021Non-GAAP diluted earnings per share of $0.14 for Q4 2022, compared to non-GAAP diluted earnings per share of $0.75 for Q4 2021GAAP diluted loss per share of $(28.00) for fiscal year 2022, compared to GAAP diluted earnings per share of $5.04 for fiscal year 2021, and included $(24.93) per diluted share due to goodwill impairment related to the GRAIL segment and $(0.55) per diluted share due to an increase in tax expense from R&D capitalization requirements that were not repealed in Q4 2022Non-GAAP diluted earnings per share of $2.12 for fiscal year 2022, compared to non-GAAP diluted earnings per share of $5.90 for fiscal year 2021, and included $(0.55) per diluted share due to an increase in tax expense from R&D capitalization requirements that were not repealed in Q4 2022 and an increase in GRAIL's non-GAAP operating loss due to a full year of consolidated results in 2022 compared to a partial year in 2021For fiscal year 2023, expect revenue to grow 7% to 10% compared to fiscal year 2022, GAAP diluted earnings per share of $0.03 to $0.28, and non-GAAP diluted earnings per share of $1.25 to $1.50SAN DIEGO, Feb. 7, 2023 /PRNewswire/ -- Illumina, Inc. (Nasdaq: ILMN) today announced its financial results for the fourth quarter and fiscal year 2022, which include consolidated financial results for GRAIL.\n\"Our fourth quarter operating results were in line with our expectations, with ongoing traction across our product portfolio amid a challenging macroeconomic environment,\" said Francis deSouza, Chief Executive Officer. \"Illumina's continued focus on innovation across multiple new products, including the NovaSeq X, the most powerful, most sustainable, and most cost-effective sequencer ever developed, have been met with strong customer interest. Our order book is exceeding expectations and we have begun shipping instruments. GRAIL ended the year with accelerating consumer excitement for its Galleri test; more than 4,500 health providers ordered the test in 2022, contributing to more than 60,000 tests ordere...